Collaboration
NeuroDex prides itself on building long-term collaborations with both academic and industry partners.
We believe collaborations bring together diverse perspectives, skills, and resources. Partnerships create new ideas and solutions. We leverage our expertise and experience in exosomes, exosome isolation, proteins, and RNA to enrich and enable access to data normally unavailable through simple blood plasma and, at times, data entirely unavailable by any other means.
Effective collaboration benefits organizations that seek to succeed in an evolving environment.
NeuroDex, a renowned company in the field of biomarker discovery, is known for its strong emphasis on forming enduring collaborations with both academic and industry partners. These partnerships have proven to be highly effective in identifying new biomarkers that are recognized as essential tools for developing therapeutics, allowing improved and better-informed clinical trial design through indicators of target engagement and those that enable patient stratification.
As a result, the verification and refinement of potential biomarkers are necessary to identify specific indicators for a desired biological state. These biomarkers can then be validated and developed into reliable clinical assays, typically antibody-based assays. This process is currently the main challenge for newly discovered protein biomarkers and their application in medicine.
One key strategy NeuroDex employs in its collaborative efforts is exploratory biomarker discovery. This approach involves working closely with partners to delve into unexplored research areas and uncover novel markers that can provide valuable insights into various aspects of disease management.
By engaging in such collaborations, NeuroDex aims to tap into its partners’ diverse expertise and knowledge. Academic institutions bring forth cutting-edge research capabilities, while industry partners contribute their extensive experience in drug development and commercialization. The synergy created through these collaborations allows for a comprehensive exploration of biomarkers across different stages of diseases and clinical trials.
NeuroDex’s exploratory biomarker discovery collaborations mainly aim to identify and monitor new markers that can effectively track drugs during clinical trials.
The success of NeuroDex’s collaborative approach lies in its ability to leverage the strengths of all involved parties. By combining resources, knowledge, and expertise, these partnerships can accelerate biomarker discovery and facilitate the translation of research findings into clinical applications.
NeuroDex’s focus on developing long-term partnerships with academic and industry collaborators distinguishes itself in the field of biomarker discovery. These collaborations aim to identify new approaches for the diagnosis, disease monitoring, treatment prediction, and patient stratification in clinical trials. By leveraging the power of collaboration, NeuroDex aims to enhance patient outcomes and drive forward healthcare innovation.
Case study-1 Target engagement biomarker.
A rare disease company with an antisense (ASO) treatment against a specific synaptic protein needs a biomarker to verify that the ASO enters the brain sufficiently to affect the therapeutic target. NeuroDex reviews the target mRNA and proteins and then works with the collaborator to develop assays for this target or utilize assays already developed by the collaborator. First, the developed immunoassays or PCR will be qualified for ensuring reliable performance, and its compatibility with human plasma will be verified. Next, NeuroDex will work with the collaborator to verify that the assay is sensitive enough to detect treatment changes. This work can occur with mice or human samples as part of the collaborator preclinical and Phase-I clinical trials.
Case study-2 Patients selection biomarker
A company developing treatment against a lysosomal protein for treating Parkinson’s disease is searching for a biomarker to select Patients with high lysosome dysfunction for their clinical trials. First, NeuroDex will test its already developed autophagy/lysosome biomarkers LC3 and Cathepsin D and discuss additional targets that are more directly linked with the collaborator treatment. Then NeuroDex will qualify the assays to ensure reliable performance. Next, NeuroDex and the collaborator will discuss the best clinal testing, including mice blood samples and retrospective analysis clinical trials plasma samples. These studies can generate a patient selection strategy for the collaborator clinical trials.
Our Partners
